Last reviewed · How we verify

Cinclus Pharma Holding AB — Portfolio Competitive Intelligence Brief

Cinclus Pharma Holding AB pipeline: 0 marketed, 0 filed, 3 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 3 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Linaprazan glurate - Low dose Linaprazan glurate - Low dose phase 3 Potassium-competitive acid blocker (P-CAB) H+/K+-ATPase (gastric proton pump) Gastroenterology
Lansoprazole - Marketed approved dose Lansoprazole - Marketed approved dose phase 3 Proton pump inhibitor (PPI) H+/K+-ATPase (proton pump) Gastroenterology
Linaprazan glurate - High dose Linaprazan glurate - High dose phase 3 Potassium-competitive acid blocker (P-CAB) H+/K+-ATPase (gastric proton pump) Gastroenterology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Aga Khan University · 1 shared drug class
  2. Ahn-Gook Pharmaceuticals Co.,Ltd · 1 shared drug class
  3. Ain Shams University · 1 shared drug class
  4. AstraZeneca · 1 shared drug class
  5. AstraZeneca (originally Astra AB) · 1 shared drug class
  6. Baxter · 1 shared drug class
  7. Charles Mel Wilcox, MD · 1 shared drug class
  8. Abbott · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Cinclus Pharma Holding AB:

Cite this brief

Drug Landscape (2026). Cinclus Pharma Holding AB — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/cinclus-pharma-holding-ab. Accessed 2026-05-16.

Related